PSNL News and Press, Personalis Inc. From 08/04/21

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Record quarterly revenue of $21.7 million in the second qu...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 6 th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 17, 2021. About Personalis, Inc. Personalis...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study " Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mec...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it will release its second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. In conjunction with the release, the Company will host a conference call and webcast...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium , which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform ™. This event will detail t...

Personalis, Inc. is a global cancer genomics company offering genomic sequencing and data analytics solutions for comprehensive molecular data analysis for patient-specific cancers and immune responses. Personalis' products include: 1) ImmunoID NeXT, a universal cancer immunogenomics ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 125,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). First contracted ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021. Interested parties may access the pre-recorded and archived web...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online 2021. The presentation , titled “ImmunoID NeXT Platform® for comprehensive tumor immunogenomics and advanced biomarker d...

Analysts weigh in on potential of COVID-19 patent waiversYesterday's announcement that the U.S. would support a waiver of IP protections for COVID-19 vaccines led to a slide in vaccine makers.However, several analysts believe the potential impact may be overhyped as other countries also oppos...